Change in antihypertensive drug prescribing after guideline implementation: A controlled before and after study

BMC Family Practice

Volumn 12, Issue , 2011, Pages

  Sipilä, Raija ^a   Helin Salmivaara, Arja ^b,c   Korhonen, Maarit ^b,d   Ketola, Eeva ^e  

^a Finska Lo karforeningen Duodecim   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e Helsinki City Health Center   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; FEMALE; GENERAL PRACTICE; HUMAN; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRESCRIPTION; STATISTICS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG PRESCRIPTIONS; FEMALE; GENERAL PRACTICE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED;

EID: 80051625190     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-12-87     Document Type: Article

References (48)

1. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH, Lancet 1990 335 8693 827 838 10.1016/0140-6736(90)90944-Z 1969567 (Pubitemid 20113741)
2. Blood pressure and stroke: an overview of published reviews. Lawes CM, Bennett DA, Feigin VL, Rodgers A, Stroke 2004 35 3 776 785 10.1161/01.STR. 0000116869.64771.5A 14976329 (Pubitemid 38280858)
3. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration, Lancet 2002 360 9349 1903 1913 12493255 (Pubitemid 35472129)
4. Prevalence, awareness and treatment of hypertension in Finland during 1982-2007. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, Salomaa V, Jousilahti P, Nissinen A, Vartiainen E, Tuomilehto J, J Hypertens 2009 27 8 1552 1559 10.1097/HJH.0b013e32832c41cd 19412128
5. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. Kastarinen MJ, Salomaa VV, Vartiainen EA, Jousilahti PJ, Tuomilehto JO, Puska PM, Nissinen AM, J Hypertens 1998 16 9 1379 1387 10.1097/00004872-199816090-00019 9746125 (Pubitemid 28408421)
6. Suomalaisten sydän- ja verisuonitautien riskitekijät FINRISKI-tutkimuksessa 1982-2002. [Changes in cardiovascular risk factors in Finland in the National FINRISK Study between 1982 and 2002]. Vartiainen E, Laatikainen T, Tapanainen H, Salomaa V, Jousilahti P, Sundvall J, Salminen M, Männistö S, Valsta L, Suom laakaril 2003 58 41 4099 4106
7. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F, JAMA 2003 289 18 2363 2369 10.1001/jama.289.18.2363 12746359 (Pubitemid 37430168)
8. National Agency for Medicines and Social Insurance Institution, Finnish Statistics on Medicines 2001 Helsinki, Finland 2002
9. Verenpainetaudin hoitotasapaino ei ole Suomessa vieläkään hyvä. [Hypertension treatment in Finland still not optimal]. Varis J, Savola H, Vesalainen R, Kantola I, Suom laakaril 2008 63 40 3289 3295
10. Hypertension treatment and control in five European countries, Canada, and the United States. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M, Hypertension 2004 43 1 10 17 14638619 (Pubitemid 38031904)
11. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. EUROASPIRE II Study Group, Eur Heart J 2001 22 7 554 572 11259143
12. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, EUROASPIRE Study Group, Lancet 2009 373 9667 929 940 10.1016/S0140-6736(09)60330-5 19286092
13. Between-country variation in the utilization of antihypertensive agents: Guidelines and clinical practice. Stolk P, Van Wijk BL, Leufkens HG, Heerdink ER, J Hum Hypertens 2006 20 12 917 922 10.1038/sj.jhh.1002089 16988753 (Pubitemid 44782824)
14. Economic implications of evidence-based prescribing for hypertension: can better care cost less? Fischer MA, Avorn J, JAMA 2004 291 15 1850 1856 10.1001/jama.291.15.1850 15100203 (Pubitemid 38509497)
15. Effectiveness and efficiency of guideline dissemination and implementation strategies. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C, Health Technol Assess 2004 8 6 ii iv 1-72 15544708
16. Audit and feedback: effects on professional practice and health care outcomes. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD, Cochrane Database Syst Rev 2006 2 D000259
17. Educational outreach visits: effects on professional practice and health care outcomes. O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, Forsetlund L, Bainbridge D, Freemantle N, Davis DA, Haynes RB, Harvey EL, Cochrane Database Syst Rev 2007 4 D000409
18. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Soumerai SB, McLaughlin TJ, Avorn J, Milbank Q 1989 67 2 268 317 10.2307/3350142 2698446 (Pubitemid 20278773)
19. Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. Figueiras A, Sastre I, Gestal-Otero JJ, J Eval Clin Pract 2001 7 2 223 241 10.1046/j.1365-2753.2001. 00234.x 11489046 (Pubitemid 32489014)
20. Rational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice [ISRCTN48751230]. Fretheim A, Oxman AD, Treweek S, Bjorndal A, BMC Health Serv Res 2003 3 1 5 10.1186/1472-6963-3-5 12657163
21. Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention. Fretheim A, Oxman AD, Havelsrud K, Treweek S, Kristoffersen DT, Bjorndal A, PLoS Med 2006 3 6 134 10.1371/journal.pmed.0030134 16737346 (Pubitemid 43987820)
22. Rational Prescribing in Primary care (RaPP): process evaluation of an intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs. Fretheim A, Havelsrud K, Oxman AD, Implement Sci 2006 1 19 10.1186/1748-5908-1-19 16934153
23. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice. Fretheim A, Aaserud M, Oxman AD, PLoS Med 2006 3 6 216 10.1371/journal.pmed.0030216 16737349 (Pubitemid 43987821)
24. Facilitating as a guidelines implementation tool to target resources for high risk patients-the Helsinki Prevention Programme (HPP). Sipila R, Ketola E, Tala T, Kumpusalo E, J Interprof Care 2008 22 1 31 44 10.1080/13561820701832581 18202984 (Pubitemid 351146906)
25. Evidence in action - guidelines directing workload. Sipila R, Ketola E, Tala T, Klockars M, Qual Saf Health Care 2010
26. The SOTKAnet indicator bank. http://uusi.sotkanet.fi/portal/page/portal/ etusivu
27. Evidence in action-guidelines directing workload. Sipila R, Ketola E, Tala T, Klockars M, Qual Saf Health Care 2010 2010 19 6 514 518 Epub 2010 Apr 3 10.1136/qshc.2008.027987
28. The Nordic countries as a cohort for pharmacoepidemiological research. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT, Basic Clin Pharmacol Toxicol 2010 106 2 86 94 10.1111/j.1742-7843.2009.00494.x 19961477
29. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc/structure-and-principles/
30. Designing and evaluating complex interventions to improve health care. Campbell NC, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F, Guthrie B, Lester H, Wilson P, Kinmonth AL, BMJ 2007 334 7591 455 459 10.1136/bmj.39108. 379965.BE 17332585 (Pubitemid 46586602)
31. How physicians choose drugs. Denig P, Haaijer-Ruskamp FM, Zijsling DH, Soc Sci Med 1998 27 12 1381 1386
32. Does comorbidity explain trends in prescribing of newer antihypertensive agents? Greving JP, Denig P, van der Veen WJ, Beltman FW, Sturkenboom MC, de Zeeuw D, Haaijer-Ruskamp FM, J Hypertens 2004 22 11 2209 2215 10.1097/00004872-200411000-00025 15480107 (Pubitemid 39463816)
33. Improving adherence to guidelines for hypertension drug prescribing: cluster-randomized controlled trial of general versus patient-specific recommendations. Goldstein MK, Lavori P, Coleman R, Advani A, Hoffman BB, Am J Manag Care 2005 11 11 677 685 16268751 (Pubitemid 41608209)
34. Academic detailing to improve antihypertensive prescribing patterns. Siegel D, Lopez J, Meier J, Goldstein MK, Lee S, Brazill BJ, Matalka MS, Am J Hypertens 2003 16 6 508 511 10.1016/S0895-7061(03)00060-8 12799103 (Pubitemid 36667809)
35. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Furberg CD, Piller LB, Pressel SL, Whelton PK, ALLHAT Collaborative Research Group, Arch Intern Med 2010 170 10 851 858 10.1001/archinternmed.2010. 130 20498411
36. Is physician adherence to prescription guidelines a general trait of health care practices or dependent on drug type? - a multilevel logistic regression analysis in South Sweden. Ohlsson H, Merlo J, Pharmacoepidemiol Drug Saf 2009 18 8 682 690 10.1002/pds.1767 19437457
37. Monella diabeetikolla jopa vuosien viive lääkeostojen erityiskorvaukseen. Virta L, Helenius H, Klaukka T, Suom laakaril 2008 63 12-13 1178 1181
38. Drug treatment for hypertension in Finnish primary health care. Wallenius S, Kumpusalo E, Parnanen H, Takala J, Eur J Clin Pharmacol 1998 54 9-10 793 799 10.1007/s002280050553 9923586 (Pubitemid 29024216)
39. Measuring prescribing improvements in pragmatic trials of educational tools for general practitioners. Maclure M, Nguyen A, Carney G, Dormuth C, Roelants H, Ho K, Schneeweiss S, Basic Clin Pharmacol Toxicol 2006 98 3 243 252 10.1111/j.1742-7843.2006.pto-301.x 16611198
40. Hypertension (online). Current Care Guideline. Working group set up by the Finnish Medical Society Duodecim and the Finnish Hyperention Society, Helsinki: the Finnish Medical Society Duodecim 2009 http://www.kaypahoito.fi
41. Is it possible to measure prescribing quality using only prescription data? Andersen M, Basic Clin Pharmacol Toxicol 2006 98 3 314 319 10.1111/j.1742-7843.2006.pto-411.x 16611208
42. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Hermanides HS, Hulscher ME, Schouten JA, Prins JM, Geerlings SE, Clin Infect Dis 2008 46 5 703 711 10.1086/527384 18230045 (Pubitemid 351321554)
43. Prescribing quality indicators of type 2 diabetes mellitus ambulatory care. Martirosyan L, Braspenning J, Denig P, de Grauw WJ, Bouma M, Storms F, Haaijer-Ruskamp FM, Qual Saf Health Care 2008 17 5 318 323 10.1136/qshc.2007. 024224 18842968
44. Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners. Muijrers PE, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA, Eur J Clin Pharmacol 2004 60 10 739 746 10.1007/s00228-004-0821-5 15517226
45. Comparison of indicators assessing the quality of drug prescribing for asthma. Veninga CC, Denig P, Pont LG, Haaijer-Ruskamp FM, Health Serv Res 2001 36 1 Pt 1 143 161 11324741 (Pubitemid 32374389)
46. Research methods used in developing and applying quality indicators in primary care. Campbell SM, Braspenning J, Hutchinson A, Marshall MN, BMJ 2003 326 7393 816 819 10.1136/bmj.326.7393.816 12689983 (Pubitemid 36523598)
47. A conceptual framework for constructing prescribing quality indicators: a proposal. DURQUIM: Drug Utilisation Research, Quality Indicator Meeting, Mechelen, Belgium, 13-15 May 2004. Haaijer-Ruskamp FM, Hoven JL
48. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004). Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH, DURQUIM Scientific Committee, Eur J Clin Pharmacol 2005 60 11 831 834 10.1007/s00228-004-0845-x 15592823 (Pubitemid 40394577)